Combined with the lengthy treatment and observation periods in these trials – up to 6 hours – oral psilocybin could prove impractical for broad therapeutic use, even if it secured FDA-approval.Įleusis formulated ELE-Psilo to deliver psilocin, the active ingredient in psilocybin, via IV infusion. Academic trials of oral psilocybin revealed considerable variability in patients’ absorption and metabolism rates at identical doses, which may result in unpredictable pharmacokinetics and pharmacodynamics. When administered orally, however, psilocybin may only be “halfway” to a modern medicine. Third-party clinical studies investigating oral psilocybin have reported compelling anti-depressant effects. ![]() healthcare infrastructure and insurance coverage and reimbursement requirements. Eleusis designed ELE-Psilo, if FDA-approved, to be compatible with existing U.S. ELE-Psilo, Eleusis’s lead drug candidate, is being developed to treat depression and is expected to enter Phase I trials in 2022, subject to regulatory authorization. Upon the close of the transaction, the combined company will be operated through Eleusis Inc., a new holding company, and will apply to have its common stock listed on Nasdaq under the symbol “ELEU.”įounded in 2013, Eleusis is dedicated to transforming psychedelics into medicines. II (“SPKB”) (NASDAQ: SPKB/SPKBU/SPKBW), a publicly traded special purpose acquisition company (“SPAC”) sponsored by an affiliate of Silver Spike Capital (“Silver Spike”), announced today that they have signed a definitive business combination agreement expected to make Eleusis a public company. LONDON and NEW YORK – Janu– Eleusis, a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. Merger also to support nationwide expansion of Eleusis’s subsidiary Andala, which manages in-network drug therapy clinics targeting the “last mile” challenge of psychedelic care delivery to address a potential $7 billion U.S.Medicines and Healthcare products Regulatory Agency’s Innovative Licensing and Access Pathway (“ILAP”), offering the potential to accelerate time to market Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |